Institute of Biomedical Research Corp. (MRES)
USD 0.01
(5.38%)
USD 0.01
(5.38%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2010 | 421.56 Thousand USD | 182.13% |
| 2009 | 149.42 Thousand USD | -19.84% |
| 2008 | 186.4 Thousand USD | 759.78% |
| 2007 | 21.68 Thousand USD | -90.46% |
| 2006 | 227.2 Thousand USD | 0.0% |
| 2004 | 91 Thousand USD | 37.86% |
| 2003 | 66.01 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2010 Q2 | 1.58 Million USD | 277.11% |
| 2010 FY | 421.56 Thousand USD | 182.13% |
| 2010 Q3 | 1.65 Million USD | 4.02% |
| 2010 Q4 | 461.33 Thousand USD | -72.1% |
| 2010 Q1 | 421.56 Thousand USD | 39.93% |
| 2009 Q4 | 301.27 Thousand USD | 58.78% |
| 2009 Q3 | 189.74 Thousand USD | 8.71% |
| 2009 FY | 149.42 Thousand USD | -19.84% |
| 2009 Q1 | 149.42 Thousand USD | -67.5% |
| 2009 Q2 | 174.54 Thousand USD | 16.82% |
| 2008 FY | 186.4 Thousand USD | 759.78% |
| 2008 Q4 | 459.79 Thousand USD | 21.82% |
| 2008 Q2 | 292.93 Thousand USD | 57.15% |
| 2008 Q1 | 186.4 Thousand USD | -75.1% |
| 2008 Q3 | 377.42 Thousand USD | 28.84% |
| 2007 FY | 21.68 Thousand USD | -90.46% |
| 2007 Q1 | 21.68 Thousand USD | -91.53% |
| 2007 Q3 | 482.83 Thousand USD | 179.92% |
| 2007 Q2 | 172.49 Thousand USD | 695.63% |
| 2007 Q4 | 748.49 Thousand USD | 55.02% |
| 2006 Q3 | 260.25 Thousand USD | 6.86% |
| 2006 Q4 | 256.08 Thousand USD | -1.6% |
| 2006 Q2 | 243.53 Thousand USD | 7.19% |
| 2006 Q1 | 227.2 Thousand USD | -10.11% |
| 2006 FY | 227.2 Thousand USD | 0.0% |
| 2005 Q1 | 92.82 Thousand USD | 2.0% |
| 2005 Q2 | 99.11 Thousand USD | 6.78% |
| 2005 Q3 | 295.62 Thousand USD | 198.27% |
| 2005 Q4 | 252.76 Thousand USD | -14.5% |
| 2004 Q3 | 84.13 Thousand USD | 9.24% |
| 2004 Q1 | 69.5 Thousand USD | 0.0% |
| 2004 FY | 91 Thousand USD | 37.86% |
| 2004 Q4 | 91 Thousand USD | 8.17% |
| 2004 Q2 | 77.01 Thousand USD | 10.8% |
| 2003 FY | 66.01 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -1436.719% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 95.546% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 99.418% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | 47.877% |
| Rebus Holdings, Inc. | 5.24 Million USD | 91.958% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 99.286% |
| Qrons Inc. | 1.48 Million USD | 71.682% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | 65.62% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 99.437% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -843.19% |
| Skye Bioscience, Inc. | 14.07 Million USD | 97.004% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 99.209% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 95.6% |
| SQZ Biotechnologies Company | 50.03 Million USD | 99.158% |
| Intellipharmaceutics International Inc. | 12 Million USD | 96.489% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 89.054% |
| Mesoblast Limited | 188.44 Million USD | 99.776% |
| Marizyme, Inc. | 26.67 Million USD | 98.42% |
| Genus plc | 485 Million USD | 99.913% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 92.785% |
| Pharming Group N.V. | 244.07 Million USD | 99.827% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 79.028% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 83.247% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 88.906% |
| ContraFect Corporation | 32.53 Million USD | 98.704% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 78.723% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 88.986% |
| IMV Inc. | 37.93 Million USD | 98.889% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 96.421% |
| MultiCell Technologies, Inc. | 1617.67 USD | -25960.198% |
| ONE Bio Corp. | 27.49 Million USD | 98.467% |
| Accustem Sciences Inc. | 1.07 Million USD | 60.938% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 99.455% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 80.068% |
| Q BioMed Inc. | 8.13 Million USD | 94.817% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 99.492% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 91.808% |
| Biomind Labs Inc. | 1.49 Million USD | 71.869% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.645% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 95.338% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 97.709% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 70.599% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -196.68% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -109.614% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 92.663% |
| GB Sciences, Inc. | 5.41 Million USD | 92.218% |
| Alpha Cognition Inc. | 7.16 Million USD | 94.116% |
| HST Global, Inc. | 593.59 Thousand USD | 28.98% |
| CSL Limited | 18.62 Billion USD | 99.998% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 66.521% |
| Halberd Corporation | 728.71 Thousand USD | 42.149% |
| Enzolytics Inc. | 365.26 Million USD | 99.885% |
| Agentix Corp. | 2.51 Million USD | 83.208% |
| Resverlogix Corp. | 67.39 Million USD | 99.374% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | 49.737% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.905% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 75.404% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 98.296% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 96.458% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 88.498% |
| AVAX Technologies, Inc. | 3.99 Million USD | 89.444% |
| Zenith Capital Corp. | 27.56 Thousand USD | -1429.138% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.968% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -76.644% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 88.711% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | 38.081% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 84.453% |
| Kadimastem Ltd | 3.5 Million USD | 87.972% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -529.873% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 99.161% |
| BioStem Technologies, Inc. | 15.9 Million USD | 97.349% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | 9.281% |
| LadRx Corporation | 2.2 Million USD | 80.842% |
| Cell Source, Inc. | 15.8 Million USD | 97.333% |
| Regen BioPharma, Inc. | 5.45 Million USD | 92.276% |
| Regen BioPharma, Inc. | 5.45 Million USD | 92.276% |
| NovAccess Global Inc. | 7.86 Million USD | 94.637% |
| Affymax, Inc. | 8.87 Million USD | 95.248% |
| Itoco Inc. | 1.65 Million USD | 74.499% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 79.451% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 93.031% |
| Mobile Lads Corp. | 1.31 Million USD | 67.905% |
| CytoDyn Inc. | 127.89 Million USD | 99.67% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -908.56% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 73.086% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 96.183% |
| SYBLEU INC | 681.41 Thousand USD | 38.133% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 93.091% |
| International Stem Cell Corporation | 5.27 Million USD | 92.011% |
| Bioxytran, Inc. | 3.24 Million USD | 87.027% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | 32.636% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 90.869% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 98.972% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 98.107% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 79.186% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 92.304% |
| Neutra Corp. | 973.52 Thousand USD | 56.697% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 98.547% |
| PureTech Health plc | 125.58 Million USD | 99.664% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 88.78% |
| IXICO plc | 1.9 Million USD | 77.816% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 97.946% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.592% |
| CSL Limited | 18.62 Billion USD | 99.998% |
| Cellectis S.A. | 249.36 Million USD | 99.831% |